All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Limited number of studies have shown that intra-arterial steroid administration (IASA) into the superior (SMA) and/or inferior mesenteric arteries (IMA) may be a feasible second-line therapy option for patients with steroid-refractory (SR) gastrointestinal (GI) acute graft-versus-host disease (aGvHD). Viktor Berczi from the Department of Radiology, Semmelweis University, Budapest, Hungary, and colleagues retrospectively analyzed the clinical effectiveness of IASA treatment in adult patients with SR GI aGvHD following hematopoietic stem cell transplantation (HSCT). The analysis was published ahead of print in Clinical Radiology.
The authors concluded that IASA “is a safe and effective method to treat SR GI aGvHD in patients who have failed to respond to first-line treatment with intravenous steroids.” Further studies are required to assess the efficacy of IASA and to identify possible prognostic factors associated with a successful outcome in this patient population.
Subscribe to get the best content related to GvHD delivered to your inbox